CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.78
0.00 (-0.38%)
▼
5d:
-12.31%
30d:
-15.27%
90d:
-28.49%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Feb 13, 2026
0d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CTOR is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CTOR is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.78, which is considered oversold relative to its 30-day fair value range of $0.82 to $0.93. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.8) compared to its historical average (2.5). At these levels, the market is pricing in 45.8% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a downtrend. The price is currently testing key support at $0.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+413.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTOR is in a downtrend. The price is currently testing key support at $0.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+413.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.82 -
$0.93
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 413.1% below Wall St target ($4.00)
- BEARISH: Market expects 45.8% growth - appears too optimistic based on history
- WARNING: Recommendation downgraded due to -12.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.82 -
$0.93
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.76
Resistance Level
$0.89
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.79
Wall Street Target
$4.00
(+413.1%)
Valuation Premium vs History
+45.8% premium
PE vs Historical
7.8 vs 2.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+45.8%
(market-implied from PE analysis)
1-Year Target
$1.14
(+46%)
2-Year Target
$1.66
(+113%)
3-Year Target
$2.42
(+210%)
3-Yr Target (if PE normalizes)
(PE: 8→3)
PE COMPRESSION
$0.77
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 03, 2026 9:48 PM ET
Data refreshes hourly during market hours. Next update: 10:48 PM
Data refreshes hourly during market hours. Next update: 10:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |